These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30396808)

  • 21. A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis.
    Shamshiripour P; Nikoobakht M; Mansourinejad Z; Ahmadvand D; Akbarpour M
    Expert Rev Vaccines; 2022 Apr; 21(4):513-531. PubMed ID: 35076331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy-Related Acute Kidney Injury.
    Manohar S; Jhaveri KD; Perazella MA
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):429-437.e1. PubMed ID: 35190109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy associated central nervous system complications in primary brain tumors.
    Mantica M; Drappatz J
    Front Oncol; 2023; 13():1124198. PubMed ID: 36874119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitor-Related Adrenal Insufficiency.
    Cherry G
    Semin Oncol Nurs; 2021 Apr; 37(2):151131. PubMed ID: 33785232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cell vaccines for brain tumors.
    Kim W; Liau LM
    Neurosurg Clin N Am; 2010 Jan; 21(1):139-57. PubMed ID: 19944973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunotherapy - immune-related adverse events and their management].
    Petrausch U
    Ther Umsch; 2019 Sep; 76(4):195-198. PubMed ID: 31498041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies.
    Rozowsky JS; Meesters-Ensing JI; Lammers JAS; Belle ML; Nierkens S; Kranendonk MEG; Kester LA; Calkoen FG; van der Lugt J
    Front Immunol; 2022; 13():864423. PubMed ID: 35464481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Combination therapies in immuno-oncology: differentiated regulatory approaches].
    Müller-Berghaus J; Sarac SB; Schüssler-Lenz M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Nov; 63(11):1388-1395. PubMed ID: 33084926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology Group.
    Withycombe JS; Carlson A; Coleman C; Leslie SL; Skeens M; Tseitlin H; Duffy EA
    J Pediatr Oncol Nurs; 2021; 38(1):16-25. PubMed ID: 33111626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-based Therapies-What the Emergency Physician Needs to Know.
    Dubbs SB; Falat C; Rosenblatt L
    Emerg Med Clin North Am; 2022 Feb; 40(1):135-148. PubMed ID: 34782084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abdominal CT manifestations of adverse events to immunotherapy: a primer for radiologists.
    Pourvaziri A; Parakh A; Biondetti P; Sahani D; Kambadakone A
    Abdom Radiol (NY); 2020 Sep; 45(9):2624-2636. PubMed ID: 32451672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role and economics of immunotherapy in solid tumour management.
    Worku DA; Hewitt V
    J Oncol Pharm Pract; 2020 Dec; 26(8):2020-2024. PubMed ID: 33036547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Immunotherapy Infusion Reactions.
    Peterson C
    Clin J Oncol Nurs; 2023 Mar; 27(2):123-128. PubMed ID: 37677832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Cutaneous Immunotherapy Toxicities.
    Altan M; Patel AB
    Clin Lung Cancer; 2021 Sep; 22(5):e783. PubMed ID: 33795210
    [No Abstract]   [Full Text] [Related]  

  • 35. Editorial: Novel diagnostic and therapeutic strategies in the management of cerebral gliomas, Volume II.
    Bosio A; Caffo M; Dipasquale A; Krengli M; Simonelli M; Lombardi G
    Front Oncol; 2023; 13():1306332. PubMed ID: 38023137
    [No Abstract]   [Full Text] [Related]  

  • 36. Understanding adverse events related to perioperative immunotherapy: A primer for thoracic surgeons.
    Jones DR
    Thorac Cancer; 2021 Sep; 12(17):2291-2292. PubMed ID: 34378865
    [No Abstract]   [Full Text] [Related]  

  • 37. Commentary: Induction Immunotherapy: Intriguing Initiative for Investigation.
    Patel SP; Onaitis M
    Semin Thorac Cardiovasc Surg; 2021; 33(3):858-859. PubMed ID: 33662553
    [No Abstract]   [Full Text] [Related]  

  • 38. Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.
    Shah PV; Arrieta VA; Lee-Chang C; Sonabend AM
    J Cell Immunol; 2020; 2(6):352-358. PubMed ID: 35592772
    [No Abstract]   [Full Text] [Related]  

  • 39. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
    Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
    J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune Checkpoints and Innovative Therapies in Glioblastoma.
    Romani M; Pistillo MP; Carosio R; Morabito A; Banelli B
    Front Oncol; 2018; 8():464. PubMed ID: 30406030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.